Phase 1, Randomized Open Label, Multiple Dose, Parallel Study To Assess The Immunogenicity Of Multiple Subcutaneous (sc) Doses Of The Proposed Pegfilgrastim Biosimilar (Pf-06881894) And Us-approved Neulasta (Registered) In Healthy Volunteers

Trial Profile

Phase 1, Randomized Open Label, Multiple Dose, Parallel Study To Assess The Immunogenicity Of Multiple Subcutaneous (sc) Doses Of The Proposed Pegfilgrastim Biosimilar (Pf-06881894) And Us-approved Neulasta (Registered) In Healthy Volunteers

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Febrile neutropenia; Neutropenia
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 27 Sep 2017 Planned End Date changed from 26 Apr 2018 to 9 Jun 2018.
    • 27 Sep 2017 Planned primary completion date changed from 26 Apr 2018 to 9 Jun 2018.
    • 27 Sep 2017 Planned initiation date changed from 18 Sep 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top